Lifecore Biomedical reported a 6.2% revenue decline to $34.2 million in Q2 2026 compared to the prior year, with net loss widening to $6.2 million. Despite this, the company added 13 new programs in the past year, including eight late-stage, strengthening its pipeline and reaffirmed its 2026 revenue guidance of $120-$125 million and Adjusted EBITDA of $20.5-$25 million. Lifecore is focused on cost reductions, productivity improvements, and transitioning its pipeline toward commercialization to achieve long-term growth and profitability targets by 2029.
Boyaa Interactive, a Hong Kong-listed gaming company, purchased an additional 115 Bitcoin, increasing its total holdings to approximately 4,316 BTC. This move places Boyaa as the 22nd largest public company Bitcoin holder worldwide. The company acqui...
Six Flags has partnered with FinTech company Upgrade to launch Flex Pay, a buy now, pay later (BNPL) option for purchasing season passes. Guests can buy passes online for $49 or more and pay in fixed monthly installments while enjoying immediate acce...
President Donald Trump declared that Canadian aircraft maker Bombardier should be banned from selling planes in the US unless they are manufactured domestically. Trump criticized Canada for unfair trade restrictions on American companies and highligh...
Xverse, a self-custodial Bitcoin wallet, has launched a pooled Bitcoin staking product allowing users to earn Bitcoin-denominated yields without giving up control of their coins. The staking uses sBTC on the Stacks network paired with STX tokens, kee...
Lion Group Holding Ltd. announced it will change its American Depositary Shares (ADS) ratio from 1 ADS per 292,500 Class A shares to 1 ADS per 5,850,000 Class A shares, effectively a 1-for-20 reverse ADS split. This change will take effect around Sep...
